Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Active Not Recruiting NCT07344584

A Prospective Pilot Study to Evaluate Safety and Effectiveness of GP0122 and GP0124 for Correction of Lines and Wrinkles in the Cheek Area

Conditions: Wrinkle Reduction

Sex: All
Ages: 18 Years – N/A
Healthy volunteers: Yes
Phase: NA
Enrollment: 60
Sponsor: Galderma R&D

Location: Galderma Investigational Site #8379 Burlington

Summary

The primary objective of the study is to evaluate the safety of GP0122 and GP0124 for the correction of lines and wrinkles in the cheek area.

Eligibility Criteria

Inclusion Criteria: Adult males or non-pregnant, non-breastfeeding adult females. 1. Participants with a GCWS At Rest score of Moderate or Severe on EACH side of the face, or Participants with a CSQS-CL score of Moderate, Severe, or Very severe on EACH side of the face. 2. Intent to undergo treatment for correction of lines and wrinkles in the cheek region. 3. Willing to abstain from any other facial plastic, surgical or cosmetic procedures in the cheek area for the duration of the study (e.g., laser or chemical resurfacing, needling, facelift, lifting threads, radiofrequency etc.). Inclusion criteria 4-5 apply only to female participants of childbearing potential: 4. Agrees to use an acceptable form of effective birth control for the duration of the study and is willing to take a urine pregnancy test (UPT) at screening, baseline and prior to receiving any study treatment. 5. Negative UPT at the screening and baseline visits. Exclusion Criteria: 1. Known/previous allergy or hypersensitivity. 2. Known/previous allergy or hypersensitivity to local anesthetics. 3. Previous facial surgery (e.g., facelift) in the treatment area that in the Treating Investigator´s opinion. 4. Any previous aesthetic procedures or implants in the treatment area. 5. Presence of any disease or lesions in the treatment area. 6. An underlying known disease, a surgical or medical condition that would expose the participant to undue risk. 7. Use of concomitant medication that have the potential to prolong bleeding times. 8. Presence of any condition or situation, which in the opinion of the Treating Investigator makes the subject unable to complete the study per protocol. 9. Women who are pregnant or breast feeding, or women of childbearing potential who are not practicing adequate contraception or planning to become pregnant during the study period.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07344584). StuddyBuddy aggregates publicly available trial information.